Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma
In conclusion, selpercatinib given prior to the initial dose of adjunctive RAI for RET-fusion positive PTC is a well-tolerated intervention that further reduces tumor burden and potentially enhances the tumorcidal effects of RAI.
Authors
- Noah Federman (ORCID: https://orcid.org/0000-0002-2627-6772)
- Harvey K. Chiu
- Masha J. Livhits (ORCID: https://orcid.org/0000-0002-8436-392X)
- Theodore S. Nowicki (ORCID: https://orcid.org/0000-0002-3815-6137)
- James X. Wu (ORCID: https://orcid.org/0000-0001-5090-7573)
Institutions
- Ronald Reagan UCLA Medical Center (US)
- UCLA Medical Center (US)
- Mattel Children's Hospital (US)
Publication Details
- Journal
- Journal of Pediatric Endocrinology and Metabolism
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1515/jpem-2024-0281
- Citations
- 4
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.43